

Molecular and Cellular Pathobiology

NAC1 Is an Actin-Binding Protein That Is Essential for Effective Cytokinesis in Cancer Cells

Kai Lee Yap1, Stephanie I. Fraley2, Michelle M. Thiaville3, Natini Jinawath3, Kentaro Nakayama5, Jianlong Wang6, Tian-Li Wang4, Denis Wirtz2, and Ie-Ming Shih3,4

Abstract

NAC1 is a transcriptional corepressor protein that is essential to sustain cancer cell proliferation and migration. However, the underlying molecular mechanisms of NAC1 function in cancer cells remain unknown. In this study, we show that NAC1 functions as an actin monomer–binding protein. The conserved BTB protein interaction domain in NAC1 is the minimal region for actin binding. Disrupting NAC1 complex function by dominant-negative or siRNA strategies reduced cell retraction and abscission during late-stage cytokinesis, causing multinucleation in cancer cells. In Nac1-deficient murine fibroblasts, restoring NAC1 expression was sufficient to partially avert multinucleation. We found that siRNA-mediated silencing of the actin-binding protein profilin-1 in cancer cells caused a similar multinucleation phenotype and that NAC1 modulated the binding of actin to profilin-1. Taken together, our results indicate that the NAC1/actin profilin-1 complex is crucial for cancer cell cytokinesis, with a variety of important biologic and clinical implications. Cancer Res; 72(16); 4085–96. ©2012 AACR.

Introduction

The Bric-a-Brac Tramtrack Broad complex (BTB) family of proteins shares a conserved BTB protein–protein interaction domain (1, 2) that is present in many DNA- and actin-binding proteins (3). Nucleus accumbens-associated 1 (NAC1) encoded by NACC1 is a member of the family and the gene was first identified by the observation that the level of NAC1 transcript was elevated in the rat nucleus accumbens in response to cocaine administration (4). Subsequently, NAC1 has been shown to participate in diverse biologic functions ranging from maintenance of stemness and proliferation of embryonic stem cells (5, 6) to the pathogenesis of human cancer (7–12). Like other members of the BTB family, the homodimeric or heterodimeric interaction mediated by its BTB domain is thought to be essential for the various functional activities of NAC1 (7).

The biologic role of NAC1 in cancer has recently emerged, as NAC1 has been found to be overexpressed in several types of human cancer including ovarian high-grade serous carcinoma, one of the most lethal neoplastic diseases in women (7, 8, 12–15). One of the mechanisms underlying NAC1 overexpression in ovarian cancer is amplification of the NAC1-encoded gene, NACC1, and analysis of The Cancer Genome Atlas (TCGA) data set shows NACC1 as one of the top potential ‘driver’ genes, showing the highest correlation between DNA and RNA copy number in ovarian high-grade serous carcinomas (11). Moreover, NAC1 upregulation is associated with disease aggressiveness and contributes to the development of chemoresistance (9, 10, 16). NAC1 is essential for survival and growth of ovarian cancer cells that overexpress NAC1 because NAC1 silencing or inactivation through ectopic expression of a deletion mutant containing only the BTB domain significantly reduced proliferation of ovarian cancer cells (7–10). Molecular mechanisms underlying the essential role of NAC1 in cancer cell survival are thought to involve multiple pathways including activation of the Gadd45 cell survival pathway (8, 9), fatty acid metabolism (17), and the HMGB-1 (high-mobility group protein B1)-mediated autophagic response (16).

In addition, the possibility that NAC1 is also involved in non-nuclear functions is indicated by the dynamic changes in subcellular localization of NAC1 at different phases of cell-cycle progression (18). In nonmitotic cells, NAC1 accumulated in distinct nuclear punctate bodies, which were dissolved into a diffuse pattern of distribution in the cytoplasm during mitosis. NAC1 nuclear bodies immediately reappeared on completion of mitosis (18), suggesting that NAC1 plays a role specifically during cell division. In this study, we sought to investigate the role of NAC1 in cell division and to identify molecular...
mechanisms by which it contributes to the survival of tumor cells. Our results show that NAC1 is an actin monomer-binding protein that regulates actin assembly in cancer cells during cytokinesis, a finding that provides a new perspective on the regulation of this fundamental biologic process in tumor cells.

Materials and Methods

Traction force microscopy

The method for embedding 0.1-μm red fluorescent protein methoxy fluorescent beads in the polymerized acrylamide substrate (0.1% methylene-bis-acrylamide and 5% acrylamide) was detailed in a previous report (19) and carried out on a glass bottom cell culture dish. A collagen layer was overlaid before SKOV3 N130 tTA cells were seeded in the dish at a suitable density for time lapse imaging. An image frame was collected once every 10 minutes to minimize the deleterious effects related to the excitation beam and to construct time lapse videos for frame-by-frame measurements of the displacement of the beads. Photomicrographs were taken at ×40 magnification to ensure sufficient resolution for resolving miniscule bead displacement using the ‘Tracking’ function in the Nikon Elements software. A total of 80 beads were tracked over the 3 conditions. The comparison of traction generated by the cells was accomplished by measuring maximal displacement of beads from origin along the x- and y-axis over time and plotting the data as a distribution.

Measurement of the contractile ring diameter

N130-induced and noninduced cells were fixed and stained for actin and 4′,6-diamidino-2-phenylindole (DAPI). Dividing cells were randomly selected (n = 20 for each condition), and the diameter of their contractile ring was directly measured using the ImageJ software (NIH, Bethesda, MD).

Plotting of cell displacement trajectories

SKOV3 and HeLa cells seeded in collagen-coated plates were imaged at low magnification every 10 minutes overnight. Using the image recognition software (Metamorph/Metavue) to accomplish tracking of the displacement of individual cells, the x and y coordinates of each cell on each frame were recorded. Stage drift of the moving stage microscope was accounted for in the calculations. Trajectories of individual cells after lentiviral short hairpin RNA (shRNA) treatments were plotted after days 3 and 6.

Establishment of primary cell cultures

To establish a primary culture of mouse lung fibroblast in the NAC1-knockout genotype, lung tissue specimens were minced, digested using collagenase (10 μg/mL) at 37°C on a rotisserie rotator, and sieved to isolate single cells. Cells were cultured in RPMI-1640 supplemented with 10% (v/v) FBS and penicillin/streptomycin (Invitrogen).

To establish a primary culture of mouse ovarian surface epithelial (mOSE) cells, we harvested the ovaries from female mice of about 10 weeks of age, and the mOSE cells were dissociated from the ovarian surface after incubating with 0.25% trypsin-EDTA at 37°C for 30 minutes followed by gentle agitation. The mOSE cells were washed and plated in Dulbecco’s Modified Eagle’s Medium-F12 (10% FBS, 5% insulin-transferrin-selenium-A, and 5% penicillin/streptomycin) in a culture dish. Fresh media was replaced every 2 to 3 days, and the cells were harvested at subconfluence for experimental purposes.

Generation of binding isotherm of NAC1/N130/profilin-1 and actin

The construction of the binding isotherm was carried out (20) with actin at fixed low concentrations in supernatant and using increasing amounts of NAC1 immobilized on anti-V5 beads to overcome the limited solubility of NAC1 in aqueous condition. The amount of actin in solution was quantified by high-resolution scanning and processing by band densitometric analysis using the BioRad ChemiDoc XRS QuantityOne software in comparison to a standard curve based on actin input and silver staining.

Cell lines and culture conditions

The cell lines used in this study, including SKOV3, HeLa, MCF7, TOV21G, and HEK293T, were purchased from American Type Culture Collection (ATCC), authenticated with short tandem repeat (STR)-based genotyping by the Fragment Analysis Facility at the Johns Hopkins University (Baltimore, MD), and matched to their profiles at the ATCC STR profile database for human cell lines. Transfection was conducted using the Lipofectamine 2000 reagent (Invitrogen). Nocodazole (100 ng/mL) was used to synchronize the cells at the mitotic phase. Nuclear and cytoplasmic purification of the lysates was carried out as described using the hypotonic swelling method: the purity of the nuclei was verified by microscopy (21).

Recombinant protein production

The NAC1-V5 construct was cloned into the pQE bacterial expression vector for recombinant protein production and purification using Ni-NTA beads (Qiagen). The insoluble protein was refolded using the Pierce protein refolding kit buffer 3 (Pierce) and immobilized on anti-V5 agarose beads (Sigma). Purified recombinant actin and profilin-1 were purchased from Cytoskeleton Inc.

Results

NAC1 inactivation or silencing causes a multinucleation phenotype in cancer cells

To document the biologic roles of NAC1 during cancer cell division, we used 2 independent and complementary approaches. First, we ectopically expressed a truncated NAC1 construct, N130, in SKOV3 human ovarian cancer cells and HeLa cells to competitively inhibit the functional activity of wild-type NAC1. The N130 construct encodes exclusively the BTB domain, which is the minimal motif required for the homodimerization of NAC1; expression of N130 has been shown to competitively disrupt NAC1 homodimerization (7). Following induction of N130 expression in SKOV3, an accumulation of polyploid cells at 4n was observed at 48 hours. After 72 hours, another distinct population of polyploid cells at 8n was detected (Fig. 1A). By direct visualization using
immunofluorescent staining, we found that the increase in DNA content corresponded to the increase in the number of multinucleated cells (Fig. 1B). The induction of the BTB domain in HeLa cells caused a similar multinucleation phenotype (Supplementary Fig. S1A and S1B). The multinucleation induced by N130 induction was also accompanied by a significant reduction in cellular proliferation in SKOV3 cells (Fig. 1C).

To control for potential nonspecific effects related to N130 expression, we ectopically expressed N130mut in SKOV3 cells. N130mut is a mutant form of N130 containing multiple introduced point mutations that prevent it from forming dimers.
with full-length NAC1 (9). The results showed that as compared with the wild-type N130, the expression of N130mut neither caused a significant reduction in cellular proliferation (Fig. 1D) nor induced multinucleation. We also conducted RNA interference to determine the specificity of N130-induced phenotypes. NAC1 expression was silenced using lentiviral shRNAs (Supplementary Fig. S2A), and like the effects of N130 induction, silencing of NAC1 in SKOV3 and HeLa cells caused multinucleation in cancer cells (SKOV3: Fig. 1E; HeLa: Supplementary Fig. S2B and S2C). We also found that shRNAs targeting NAC1 suppressed cellular proliferation in SKOV3, HeLa, and MCF7 cancer cells (Supplementary Fig. S2D), all of which express abundant NAC1 (Supplementary Fig. S2E), whereas NAC1 shRNA expression in the TOV21G tumor cell line, which has undetectable NAC1 expression (10), had a less conspicuous effect.

The multinucleation phenotype of cancer cells is caused by abscission failure during cytokinesis

Next, we applied time lapse microscopy to observe the formation of multinucleation in NAC1-inactivated (N130-induced) cancer cells. As shown in the Supplementary Videos, NAC1-inactivated cells (with N130-induction, Supplementary Video S1) and control cells (without N130-induction, Supplementary Video S2) underwent normal mitosis and displayed equatorial furrowing. However, in the later phases of cell division, NAC1-inactivated cells were characterized by incomplete constriction and abscission of the contractile ring, and as a result, many of the dividing cells became multinucleated (Supplementary Video S1). This finding was recapitulated in time lapse videos of dividing SKOV3 and HeLa cells after treatment with lentiviral NAC1 shRNAs (HeLa: Supplementary Fig. S3; SKOV3: data not shown). Whereas cells treated with control shRNA (Supplementary Fig. S3A) completed cytokinesis and formed 2 distinct daughter cells, NAC1 shRNA–treated cells failed to complete the final stage of cytokinesis and became multinucleated (Supplementary Fig. S3B).

Failure of abscission during cytokinesis of cancer cells is a consequence of a loss in traction of dividing cells, impeded constriction of their contractile rings, and reduced migration potential

We hypothesized that the defect in late cytokinesis was a result of insufficient traction of the dividing cells to facilitate cellular division. To determine the traction generated by dividing cells, we used traction force microscopy to correlate the traction generated by dividing cells with the displacement of fluorescent beads embedded directly beneath the cells in a polycrylamide substrate. Analysis of the displacement of each bead from its original location during the course of cell division revealed a significant decrease in the maximal displacement of beads by SKOV3 cells after NAC1 inactivation (Fig. 2A), suggesting that NAC1 proteins were important for the generation of traction in the dividing cancer cells. Using immunofluorescent microscopy to visualize actin structures, we compared the size of contractile rings between dividing N130-induced and noninduced cells. Although N130-induced cells correctly positioned the cleavage furrows and contractile rings, these cells displayed a larger average diameter of contractile rings than their noninduced counterparts, suggesting that the constriction of contractile rings was compromised in N130-induced cells (image: Fig. 2B, quantification: Fig. 2C). To determine whether there was a loss in migration potential of the cells after silencing of NAC1 (days 3 and 6), live cell imaging was used to follow the cell displacement trajectories during an overnight observation. After days 3 and 6 under control shRNA and NAC1 shRNA treatment, typical trajectories (red, yellow, green, blue) of SKOV3 and HeLa individual cells were plotted by their x and y coordinates (Fig. 3 and Supplementary Fig. S4) and revealed that the silencing of NAC1 caused SKOV3 and HeLa cells to undergo restricted migration and greatly reduced displacement from their original location. As early as 3 days after NAC1 silencing, both SKOV3 and HeLa cells showed restricted migration and reduced displacement from origin (Fig. 3A and Supplementary Fig. S4A). The silencing of NAC1 was sustained for as long as 6 days after shRNA treatment (Supplementary Fig. S4C). We showed that the reduction in migration and displacement of NAC1 silenced cells was also observed at day 6 of shRNA treatment in SKOV3 and HeLa cells (Fig. 3B and Supplementary Fig. S4B).

Expression of NAC1 partially rescues normal cytokinesis in Nac1-null cells

To determine whether NAC1 was essential for effective cytokinesis, we reintroduced NAC1 expression in Nac1-null cells to determine whether ectopic NAC1 would prevent the multinucleated phenotype. For this purpose, we used a Nac1 homozygous knockout (Nac1−/−) mouse in which both copies of the BTB domain of the mouse Nac1 gene were deleted (Fig. 4A). In addition, we bred Nac1 hemizygous knockout mice (Nac1+/−), and the cells isolated from those mice were analyzed in parallel. Western blot analysis showed that Nac1+/− lung fibroblasts did not express a detectable level of Nac1 protein, whereas lung fibroblasts from the Nac1−/− mice expressed detectable, albeit much less, Nac1 compared with cells isolated from wild-type Nac1+/+ mice (Fig. 4B). More importantly, we observed that the percentage of multinucleated cells (2.7%) in Nac1−/− (n = 930) was much lower than in Nac1+/− cells (23.7%; n = 1,011), whereas heterozygous Nac1 cells (Nac1+/−; n = 1,040) showed an intermediate percentage (12.7%) of multinucleated cells (Fig. 4C and D).

To determine whether the reexpression of Nac1 protein could rescue the multinucleation phenotype, NAC1 was reintroduced into Nac1−/− cells as a V5-NAC1 protein by a retroviral vector. We then quantified the number of multinucleated cells in cultures that were either treated with control virus (n = 329) or with the NAC1 expression construct virus (n = 304). We found that there was a significant reduction (28.3% to 6.25%) in the percentage of multinucleated cells after the introduction of the NAC1 expression vector (Fig. 4E). The successful introduction of NAC1 expression was confirmed by immunofluorescent detection of the V5 epitope (Fig. 4F) and by Western blot analysis (Fig. 4G). A similar result could be obtained in mOSE cells generated from the same strain of mice (Supplementary Fig. S5).
Cancer cells after profilin-1 silencing exhibit a similar multinucleation phenotype

The multinucleation phenotype observed in NAC1 inactivated or silenced cells is reminiscent of multinucleation reported in mouse chondrocytes after silencing of profilin-1 (19). In the current study, by silencing profilin-1 expression (Supplementary Fig. S6A), we were able to show the formation of multinucleated cells in SKOV3 cells (Fig. 5A) and HeLa cells (Supplementary Fig. S6B and S6C). The silencing of profilin-1 also caused a reduction in cellular proliferation in our previously examined panel of cancer cell lines, MCF7, HeLa, SKOV3, and TOV21G (Supplementary Fig. S6D). Profilin-1 is a ubiquitous actin monomer–binding protein that is known to regulate actin polymerization during cytokinesis (22–24).

The similarity of the phenotype observed in chondrocytes and tumor cells after profilin-1 silencing prompted us to investigate the possibility that NAC1 has a biologic role in cytokinesis involving profilin-1/actin complexes. Given that the known role of NAC1 involved transcription regulation, it is possible that the multinucleated phenotype induced by NAC1 knockdown was mediated by downregulation of profilin-1 expression. To test this possibility, we used Western blot analysis but did not observe significant changes in the levels of profilin-1 protein expression between cells treated with NAC1 shRNA and control shRNA (Supplementary Fig. S2A, right), suggesting that the phenotype generated by the knockdown of NAC1 was not due to reduced profilin-1 levels.

Next, using immunofluorescent microscopy, we found that NAC1 and profilin-1 colocalized during cell division in HeLa cells (Fig. 5B). Nuclear and cytoplasmic protein extracts from HeLa and MCF7 cells were used for Western blot analysis to analyze the distribution of the proteins in the cellular compartments. Interestingly, NAC1 was mainly found in the nuclear extract during interphase, with low levels in the cytoplasm, whereas profilin-1 was almost exclusively detected in the cytoplasmic extract (Fig. 5C). When we mitotically arrested cells with the microtubule-depolymerizing drug, nocodazole, and examined NAC1 levels by Western blot analysis in the cytoplasmic fraction, we found that there was a significant amount of NAC1 in the cytoplasmic fraction as compared with the chromosomal fraction (Supplementary Fig. S6E). This cell-cycle–dependent localization of NAC1 was previously described in an earlier publication (18). Thus, during cell division, NAC1 abundantly accumulated in the cytoplasm where it could colocalize with profilin-1.
Accordingly, co-immunoprecipitation experiments were conducted to determine whether NAC1 and profilin-1 interacted in vivo. We found that endogenous NAC1 and profilin-1 could be co-immunoprecipitated from lysates prepared from HeLa and MCF7 cells (Fig. 5D). Both HeLa and MCF7 cells have abundant NAC1 expression as previously documented (Supplementary Fig. S2E). Reciprocal co-immunoprecipitation experiments using anti-profilin-1 for pull-down and anti-NAC1 for Western blot analysis detection confirmed that NAC1 and profilin-1 were constituents of the same protein complexes.

**NAC1 interacts directly with actin monomers**

As profilin-1 is an actin-binding protein and plays a pivotal role in actin polymerization (23), we investigated the possibility that NAC1 also interacted with actin. Co-immunoprecipitation experiments using cytoplasmic extracts of MCF7 cells showed that NAC1 co-immunoprecipitated with actin monomers in cytoplasmic but not in nuclear lysates (Fig. 6A). To further determine whether the NAC1–actin interaction was direct or depended on profilin-1, we conducted an *in vitro* binding assay using NAC1-V5, profilin-1, and actin recombinant proteins. After incubating NAC1-V5 and actin, we observed that actin could be co-eluted with NAC1 on anti-V5 agarose beads. In the absence of NAC1-V5 protein, however, actin was not retained on the anti-V5 beads and was undetectable in the eluted protein fraction (Fig. 6B). We also conducted quantitative binding assays using a method previously described (20) to characterize the protein interactions (actin standard curve documented in Supplementary Fig. S7A). A fixed amount of actin or profilin-1 protein was incubated with increasing amounts of NAC1-V5-beads. After incubation, the amount of unbound actin or profilin-1 in the supernatant was measured and used to determine the bound fraction. We found that recombinant NAC1 was unable to show a dose-dependent co-binding of profilin-1 in the binding affinity assay (Supplementary Fig. S7B). On the other hand, we were able to show the dose-dependent binding of NAC1 and actin in the binding affinity assay (Fig. 6C). Taken together, these results...
Figure 4. Expression of NAC1 partially rescues multinucleation in Nac1−/− cells. A, DNA gel electrophoresis validates the two knockout alleles (440 bp) in Nac1−/− mice and one knockout and one wild-type allele (480 bp) in Nac1+/− mice. B, Western blot analysis shows differential protein expression levels of NAC1 in lung fibroblasts isolated from the respective genotypes. C, Immunofluorescent staining of α-tubulin facilitates the quantification of cells exhibiting multinucleation. Cells were counterstained with DAPI to reveal nuclei. Arrowheads indicate multinucleated cells. Scale bar, 50 μm. D, Number of multinucleated cells was presented as a percentage in primary lung fibroblast cultures established from different Nac1 genotype mice. There is a significant difference in the proportion of multinucleated cells between different Nac1 genotypes (***, P < 0.0001; χ² contingency table). E, NAC1 was ectopically expressed in Nac1−/− cells, and its expression was associated with a significant decrease in the percentage of multinucleated cells as compared with control virus-treated group (***, P < 0.0001; χ² contingency table). F, Double immunofluorescent staining of α-tubulin and V5 (to detect NAC1-V5) facilitates the quantification of cells exhibiting multinucleation after expression of NAC1. Cells were counterstained with DAPI to reveal nuclei. Arrowheads denote multinucleated cells. Scale bar, 50 μm. G, Western blot analysis verified the expression of NAC1-V5 after viral transduction. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
indicated a direct protein–protein interaction between NAC1 and actin but not between NAC1 and profilin-1, although in vivo co-immunoprecipitation reactions (Fig. 5D) showed that NAC1 and profilin-1 were in the same protein complexes.

The quantitative binding assays revealed that NAC1-V5 and actin interacted with a $K_d$ of 0.78 μmol/L (Fig. 6C). As a negative control, an irrelevant protein of similar molecular weight as NAC1, Notch3-ICD-V5 was analyzed in parallel to show the assay specificity (Supplementary Fig. S7C). To determine the domain of the NAC1 protein that was involved in the direct interaction with actin, we generated another recombinant NAC1 protein composed of only the BTB domain (N130-V5). We carried out a similar quantitative binding assay between NAC1 protein and profilin-1. The quantitative binding assays revealed that NAC1-V5 and profilin-1 interacted with a $K_d$ of 0.78 μmol/L (Fig. 6D). To further support the finding that the BTB domain of NAC1 is able to modulate binding between profilin-1 and actin, we generated another recombinant profilin-1 mutant, PFN1Y60A, which has been shown to exhibit reduced actin-binding activity (25). We also generated PFN1R89L, a control that does not affect the binding between profilin-1 and actin (ref. 26; Fig. 7A).

As verified by our protein co-immunoprecipitation experiments, PFN1Y60A exhibited diminished binding to actin whereas mutant PFN1R89L did not (Fig. 7B). We expressed wild-type NAC1 (Supplementary Fig. S8C1) was responsible for its interaction with the profilin-1/actin complex.

**NAC1 is able to modulate binding between profilin-1 and actin monomers**

Because the interaction between actin and profilin-1 is known to be critical for cytokinesis (22), our results suggested that the interaction between NAC1 and actin could modulate the binding between profilin-1 and actin. We used Nac1−/− lung fibroblasts as a cellular system to test this hypothesis. Because of the relatively high binding affinity between actin and profilin-1, we created a profilin-1–mutant, PFN1Y60A, which has been shown to exhibit reduced actin-binding activity (25). We also generated PFN1R89L, a control that does not affect the binding between profilin-1 and actin (ref. 26; Fig. 7A). As verified by our protein co-immunoprecipitation experiments, PFN1Y60A exhibited diminished binding to actin whereas mutant PFN1R89L did not (Fig. 7B). We expressed wild-type profilin-1 (PFN1) using lentiviral shRNA causes a similar multinucleation phenotype as NAC1 silencing in SKOV3 cells. Cells were counterstained with DAPI. Scale bar, 50 μm. B, NAC1 and profilin-1 colocalize in the same cellular compartment during cell division. Images were obtained using confocal microscopy. Scale bar, 10 μm. C, Western blot (WB) analysis of proteins localized in nuclear and cytoplasmic compartments of interphase cells (data are from unsynchronized cells). D, reciprocal protein co-immunoprecipitation (IP) experiments showed that NAC1 complexed with profilin-1 in HeLa and MCF7 cells expressing abundant NAC1, lysates that were transfected with the profilin-1-GST expression construct. Ab, antibody; GST, glutathione S-transferase.
and mutant profilin-1 in Nac1−/− lung fibroblasts previously transfected with a NAC1-V5 expression vector or an empty vector. We observed that in the presence of NAC1-V5, the actin-binding activity of profilin-1 decreased, particularly for PFN1Y60A in which actin-binding activity was totally abrogated (Fig. 7C, right). Conversely, in fibroblasts without NAC1 expression, PFN1 Y60A-mutant co-immunoprecipitated with actin (Fig. 7C, left), suggesting that the presence of NAC1 inhibited the interaction between profilin-1 and actin.

Discussion

The results from the current study unveil a novel mechanism by which cancer cells facilitate their incessant cellular divisions, which is the cardinal feature of neoplastic diseases. Our results indicate that abundant NAC1 proteins in cancer cells promote cytokinesis through modulating the interaction of actin and profilin-1, ensuring an effective completion of cellular division in highly proliferative tumors. The observation that NAC1-overexpressing tumor cells develop molecular dependence on NAC1 protein (7–9) promises future exploitation by targeting NAC1 as a cytostatic cancer therapy aimed at compromising cytokinesis in cancer cells.

Cytokinesis is a highly complex event involving a cascade of sequential and well coordinated molecular processes (27). In eukaryotic cells, this is made possible by chromosomal segregation and Rho GTPase signaling followed by the effective...
Assembly and constriction of contractile rings by non-muscle myosin II, actin, and its binding partners before actual cellular division occurs (27–29). For example, disruption of Rho GTPase signaling, which is known to regulate the actin cytoskeleton, can result in the misalignment of the cleavage furrow and contractile ring (30). Cytokinesis failure can also result from the slow ring closure of the contractile apparatus due to inadequate constriction, leading to a cytoplasmic connection between daughter cells that precedes furrow regression (31). As shown in this study, inactivation or silencing of NAC1 did not cause detectable aberrations in early cytokinetic events such as chromosome separation or formation and positioning of cleavage furrow and contractile ring; however, NAC1 inactivation or silencing resulted in the inability of the dividing cells to generate the force required to constrict the contractile actomyosin ring or to generate sufficient traction to move the dividing cells apart to make the “final cut,” impeding abscission and resulting in incomplete partitioning of the cytoplasm of the cell (29). This finding is consistent with previous studies showing that traction force is required for complete cytokinesis in dividing cells in Dictyostelium and mouse chondrocytes (19, 27).

The actin-binding property of NAC1 and its ability to modulate the interaction between profilin-1 and actin may account for the defective cytokinesis observed in tumor cells after NAC1 inactivation or knockdown. Because actin structures have been shown to be important for the regulation of cell shape and movement (32), the demonstration that NAC1 is an actin-binding protein could also explain previously reported findings that reducing NAC1 expression by RNA interference decreased cellular motility (10, 33). Apropos to these observations, it has been well established that prolin-1, which is a ubiquitous actin monomer regulating actin polymerization. Although NAC1 may decreases the binding of profilin-1 to actin, C, interaction of profilin-1 and actin could be modulated by the presence of NAC1. Nac1−/− lung fibroblast cells were co-transfected with the profilin-1–GST constructs in the presence or absence of the NAC1 expression plasmid. Cell lysates were immunoprecipitated for the profilin-1–GST proteins using glutathione agarose beads and immunoblotted with an anti-actin antibody. Presence of NAC1 protein reduces the binding of profilin-1 and actin, especially for PFN1Y60A mutant where actin binding is almost completely abrogated. GST, glutathione S-transferase; WB, Western blot.
the development of molecular dependence on NAC1. Thus, inactivation or knockdown of NAC1 would not allow completion of cytokinesis in those cancer cells. This indicates the possibility of targeting NAC1 in cancer cells for maintenance cancer therapy. This is important because the conventional cytotoxic chemotherapy is always complicated by its cytotoxic effects on normal cells. Unlike conventional cytotoxic drugs, NAC1-targeted antitumor strategies involving pharmacologic compounds that disrupt protein–protein interactions between the well-characterized BTB domains of NAC1 (35) and actin are likely to have minimal cytotoxicity for normal cells because cancer cells are more likely "addicted" to NAC1 overexpression.

This finding is of great interest in light of the lack of actin-targeting agents in the arsenal of anti-cancer drugs, a consequence of the fact that the known reagents target the actin assembly in both cancer and normal cells (36). That disrupting NAC1 BTB domain protein interactions as a cancer chemotherapeutic strategy is feasible is suggested by the use of peptidomimetic and small-molecule inhibitors to disrupt the BTB interacting domain of BCL6, which has been shown to be effective in suppressing tumor growth in B-cell lymphomas (37–39). Triggering cytokinesis failure in cancer cells could give rise to either chromosomal instability or apoptosis. However, it is expected that in the presence of the functional p53, cells that were treated with drugs blocking cytokinesis will acquire an extreme multiploidy phenotype and undergo rapid cell death or senescence (31, 40).

In summary, our findings provide cogent evidence that NAC1 is a member of the actin-binding protein family. The potential involvement of NAC1 in regulating actin organization during late-stage cytokinesis represents a functional property well beyond its canonical function as a transcriptional regulator. By highlighting the participation of NAC1 in regulation of the actin assembly in cancer cells, our results should have profound implications on the study of actin biology in cancer and should advance our basic understanding of the process of cytokinesis.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: K.L. Yap, T.-L. Wang, L.-M. Shih
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K.L. Yap, S.J. Fraley, J. Wang, D. Wirtz
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K.L. Yap, M.M. Thiaville, K. Nakayama, T.-L. Wang, D. Wirtz, L.-M. Shih
Writing, review, and/or revision of the manuscript: K.L. Yap, S.J. Fraley, M.M. Thiaville, J. Wang, L.-M. Shih
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.J. Fraley, N. Jinawath, L.-M. Shih
Study supervision: T.-L. Wang, D. Wirtz, L.-M. Shih

Developed biophysical methods of analysis: S.J. Fraley
Initiated protein interaction studies for screening candidate genes: M.M. Thiaville
Built initial constructs and validated them in vitro: N. Jinawath, K. Nakayama
Contributed the Nac1 knockout mouse: J. Wang

Acknowledgments
The authors thank Bin Guan, Alexander Stockeck, Xu Chen, and Pei-Hsun Wu for helpful discussions.

Grant Support
This study was supported by NIH/NCI grants RO1CA103937, RO1CA129080, RO1CA148826, and U54CA148868.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 30, 2012; revised June 4, 2012; accepted June 5, 2012; published OnlineFirst July 3, 2012.

References


NAC1 Is an Actin-Binding Protein That Is Essential for Effective Cytokinesis in Cancer Cells

Kai Lee Yap, Stephanie I. Fraley, Michelle M. Thiaville, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-0302

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/07/10/0008-5472.CAN-12-0302.DC1

Cited articles
This article cites 39 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/16/4085.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/72/16/4085.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.